A1480LS

A1480LS (1-20 mg/kg; p.o.; twice) produces dose-dependent relief of mechanical allodynia in a rat CFA inflammatory pain model by inhibiting peripheral DAGL without altering brain 2-AG levels, with an ED₅₀ of 7.7 mg/kg^[1].
A1480LS (15, 20 mg/kg; p.o.) rapidly alleviates and continuously inhibits paclitaxel-induced mechanical hyperalgesia in rats during 5 consecutive days of administration. It also reverses and maintains CCI-induced mechanical allodynia in rats to the sham operation level, while restoring the injury-induced elevated levels of 2-AG and AA in the sciatic nerve to normal, without affecting the levels of these lipids in the brain^[1].
A1480LS (1 mg/kg; i.v.) selectively inhibits the activity of HT and WDR-like dorsal horn neurons in anesthetized CCI rats without altering the activity of LTMRs, indicating that it suppresses spinal nociceptive sensory input^[1].
A1480LS (8-30 mg/kg; p.o.) does not modulate PTZ-induced seizure susceptibility or brain 2-AG levels in rats, is well tolerated in rats, with only mild, transient reduction in abdominal muscle tone observed in some animals; these findings indicate that it poses no central nervous system epileptogenic risk^[1].